News Room

  • November 20, 2014
    Altasciences Further Expands its Footprint with Algorithme Pharma USA

    Altasciences is pleased to announce the opening of Algorithme Pharma USA, further expanding the Company’s North American footprint and ability to provide comprehensive Bioequivalence and Phase I/IIa clinical drug development capabilities in the United States.

  • November 12, 2014
    Vince & Associates Clinical Research Holiday Lights Display to Raise Money for Children’s Mercy and Make-A-Wish® Missouri

    Vince & Associates will kick off its 9th Annual holiday lights display on Friday, November 14th. This year will differ from years past as Vince & Associates will be collecting donations for Children’s Mercy and Make-A-Wish Missouri.

  • October 31, 2014
    International Clinical Trials Magazine – Used and Abused

    Delivering effective medication may be the end aspiration of the trial process, but sometimes there is a darker side as the drug falls foul to misuse and abuse. Now gaining more attention, human abuse liability studies of recreational drug users aim to tackle this.

  • October 1, 2014
    Vince & Associates Clinical Research Continues Collaborating with Cambridge Cognition for Electronic Visual Analog Scales for Human Abuse Liability Trials

    Vince & Associates Clinical Research, a premier provider of early phase clinical research services with over 100 beds, continues its collaboration with Cambridge Cognition on electronic Visual Analog Scales (eVAS) for Human Abuse Liability (HAL) clinical trials. Secondary to the guidance documents released in recent years by the FDA on abuse liability assessments for new chemical entities and abuse deterrent formulations; there has been an increased demand for HAL clinical trials. In response to the guidance documents, Vince & Associates formed a collaboration with Cambridge Cognition, the global leader in touchscreen cognitive assessments for clinical trials, and together these companies have been successfully conducting HAL trials for years.

  • September 16, 2014
    Vince & Associates Clinical Research Completes Enrollment of Human Abuse Liability Study for Centanafadine for Adult ADHD

    Vince & Associates Clinical Research, a premier provider of early phase clinical research services, announced the completion of enrollment of a human abuse liability (HAL) clinical trial of centranafadine (formerly EB-1020). Centranafadine is a novel non-stimulant being developed by Neurovance of Cambridge, MA for the treatment of adult attention deficit hyperactivity disorder (ADHD).

Pages